Company Encyclopedia
View More
name
BNY Mellon US Small Cap Core Equity ETF
BKSE.US
News
View More

Top 10 US Stock Losers (12.4)

Symbotic(SYM) fell 17.4%, with a trading turnover 592.0 Million USD, and a year-to-date rose 155.1%. Build A Bear(BBW) fell 15.54%, with a trading turnover 76.7 Million USD, and a year-to-date rose 7.1%. Capricor Therap(CAPR) fell 15.22%, with a trading turnover 219.7 Million USD, and a year-to-date rose 84.1%.

LB Select·
US
SYM
-17.40%
US
BBW
-15.54%
US
CAPR
-15.22%
LB Select·
US
SYM
-17.40%
US
BBW
-15.54%
US
CAPR
-15.22%

VP Dolev Surrenders 3,183 Of Onto Innovation Inc [ONTO]

VP Dolev Ido of Onto Innovation Inc surrendered 3,183 shares back to the company to cover option exercise costs and tax liabilities. The transaction was filed with the SEC on December 4, 2025, at a price of $154.01 per share, totaling $490,214. Dolev's ending holdings are 23,915 shares directly.

Reuters·
US
ONTO
+0.84%
Reuters·
US
ONTO
+0.84%

Attention Long-Term Shareholders of Cytokinetics, Inc.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Cytokinetics, Inc. (NASDAQ: CYTK), Molina Healthcare, Inc. (NYSE: MOH), Synopsys, Inc. (NASDAQ: SNPS), and WEBTOON Entertainment Inc. (NASDAQ: WBTN) due to alleged breaches of fiduciary duties by certain officers and directors. The investigations focus on various issues including misleading statements regarding FDA applications, undisclosed material facts, inflated growth figures, and misleading IPO disclosures. Shareholders who purchased shares before specific dates are encouraged to contact the firm for potential corporate reforms and compensation.

GlobeNewswire·
US
CYTK
+2.91%
US
MOH
+0.99%
GlobeNewswire·
US
CYTK
+2.91%
US
MOH
+0.99%

Dir Henderson Sells 8,750 ($559.1K) Of Cytokinetics Inc [CYTK]

Director John Tannahill Henderson of Cytokinetics Inc sold 8,750 shares for $559,125, as disclosed in a Form 4 filed with the SEC. The sale was part of a prearranged trading plan (10b5-1). Henderson's ending holdings are 74,661 shares. The Washington Service offers insider trading analysis and data services.

Reuters·
US
CYTK
+2.91%
Reuters·
US
CYTK
+2.91%

Cytokinetics Director John T. Henderson Reports Sale of Common Shares

John T. Henderson, Director at Cytokinetics Incorporated, reported the sale of common shares. The original filing is available via EDGAR, published by Cytokinetics on December 02, 2025. This news brief is AI-generated by Public Technologies and is not financial advice.

Reuters·
US
CYTK
+2.91%
Reuters·
US
CYTK
+2.91%
© 2025 Longbridge｜Disclaimer